#Deramiocel
LightNews LightNews
pantheradraws.bsky.social
Deramiocel FDA approval coming in August (Capricor is the creator of the drug in partnership with Nippon-Shinyaku). While not a genetic cure, it could provide similar benefit (via quarterly IV infusions). Hopefully, soon I'll be healing 'cause this whole thing has been hard. More updates to come!🤞✨
April 3, 2026 at 4:58 PM
pantheradraws.bsky.social
4. Also applying for disability income since I've been unable broaden my art output since 2025 with the current state of my disease. 5. Making it through (and healing when the cure comes) is my priority. Fingers crossed for deramiocel, perhaps getting FDA approval in November.
August 25, 2026 at 7:27 PM
thelancetneuro.bsky.social
New online @thelancet.com: the HOPE-3 trial of deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy www.thelancet.com/journals/lan...
Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial
Deramiocel safely slows disease progression in advanced DMD, preserving skeletal muscle function. Administered quarterly in a simple outpatient regimen, deramiocel is a promising treatment for DMD, ag...
www.thelancet.com
July 29, 2026 at 2:58 PM
sarahkarlin-smith.bsky.social
Told Prasad and Verdun disagreed over the regulation of CAR-T products, as well as Capricor Therapeutics’ Duchenne muscular dystrophy drug deramiocel (CAP-1002).
June 19, 2025 at 1:09 PM
pupfiction.bsky.social
Medicine moves on improving peoples lives while others in the US seek to deride and hobble it 🧪

Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial
www.sciencedirect.com/science/arti...
July 30, 2026 at 5:56 AM
stemcells.bsky.social
Could Capricor's report of strong data on deramiocel cell therapy for Duchenne muscular dystrophy spark FDA approval? ipscell.com/2025/12/coul... #stemcells #stemcell
Could Capricor's report of strong data on deramiocel for Duchenne spark FDA approval? - The Niche
Stem cell biologist discusses the meaning of more Capricor data on cell therapy deramiocel for Duchenne Muscular Dystrophy.
ipscell.com
December 4, 2025 at 5:18 PM
stemcells.bsky.social
Capricor has a new paper this AM on HOPE-3 deramiocel DMD trial on day of its ad comm mtg w/ FDA. "Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial" www.thelancet.com/journals/lan...
Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial
Deramiocel safely slows disease progression in advanced DMD, preserving skeletal muscle function. Administered quarterly in a simple outpatient regimen, deramiocel is a promising treatment for DMD, ag...
www.thelancet.com
July 29, 2026 at 3:48 PM
biologist077.bsky.social
For Duchenne MD, heart problems are a big deal. Early trial data shows a cell therapy called Deramiocel reduced myocardial fibrosis (that's heart scarring) in boys. Promising for a disease with few options for cardiac issues.
Capricor's Deramiocel Cell Therapy Shows Significant Reduction in Cardiac Fibrosis for Duchenne Musc
New data from the Phase 3 HOPE-3 clinical trial indicates that Capricor Therapeutics' investigational cell therapy, Deramiocel, significantly reduced myocardial fibrosis in boys with Duchenne muscular
www.capricor.com
March 14, 2026 at 2:04 AM
kgusler.bsky.social
Bloodstream-delivered cell therapy slows muscle decline in young people with Duchenne muscular dystrophy, trial finds
A cell therapy called deramiocel could slow muscle weakening in boys and young men with advanced Duchenne muscular dystrophy (DMD) and may also slow heart damage in those who already have heart muscle...
medicalxpress.com
July 30, 2026 at 12:05 PM
aktiego.bsky.social
Capricor's deramiocel review just got pushed to November 22, and the stock loved it. New data, a narrower ask, and a market still betting on approval. Details: aktiego.com/sectors/biot... #Deramiocel #DMD
Disclaimer: This is not financial advice. For informational purposes only.
August 25, 2026 at 11:16 PM
stemcells.bsky.social
Encouraging sign as Capricor seeks FDA approval of deramiocel for Duchenne Muscular Dystrophy based on encouraging data ipscell.com/2024/11/capr... #stemcells
Capricor seeks FDA approval of deramiocel for Duchenne based on encouraging data - The Niche
Stem cell biologist discusses very encouraging data from Capricor on Duchenne Muscular Dystrophy and future prospects.
ipscell.com
November 8, 2024 at 4:21 PM
medpagetoday.com
FDA scientists said that investigational deramiocel, a stem cell treatment for Duchenne muscular dystrophy, did not meet its primary endpoint in a phase III trial, despite data presented at the AAN annual meeting to the contrary.
https://www.medpagetoday.com/neurology/generalneurology/122368
FDA Scientists Raise Questions About Duchenne Drug
Agency says deramiocel did not meet phase III trial endpoints, contrary to reported data
www.medpagetoday.com
July 28, 2026 at 9:39 PM
russellrogers.bsky.social
Pleased to share out latest work on cell therapy for #Duchenne. We show #deramiocel therapy initiated early protects against disease-related decline in muscle function.

@eduardomarban.bsky.social @smidtheart.bsky.social @stemcellreports.bsky.social @mda.org
Long-term preservation of muscle function and structure by repeated administration of cardiosphere-derived cells in mdx mice
Duchenne muscular dystrophy (DMD) is a progressive disease associated with functional decline. Chronic administration of cardiosphere-derived cell therapy prevents disease-related functional decline f...
www.cell.com
March 20, 2025 at 8:25 PM
dmdwarrior.com
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency 💯

Source: bit.ly/3Zg49Vq

#dmd #bmd #celltherapy #dmdwarrior #dmdwarriors
#musculardystrophy #carpicor #ema #atmp
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
November 20, 2024 at 5:00 PM
drtimos.bsky.social
Signal or noise? > FDA Panel Votes Against Deramiocel for Duchenne
cardiomyopathy - CGTLive® >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #competitivemarketing #biotech #pharma
FDA Panel Votes Against Deramiocel for Duchenne cardiomyopathy - CGTLive®
FDA Panel Votes Against Deramiocel for Duchenne cardiomyopathy  CGTLive®
dlvr.it
August 14, 2026 at 1:55 PM
dmdwarrior.com
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchenne #musculardystrophy #Capricor #Deramiocel #fda
Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy -If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy. -BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku.
January 2, 2025 at 7:40 PM
drtimos.bsky.social
Signal or noise? > FDA Panel Rejects Deramiocel Evidence as Lancet Validates
Same Trial Data - Tech Times >> Comment below! #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #biotech #healthcare #competitivemarketing
FDA Panel Rejects Deramiocel Evidence as Lancet Validates Same Trial Data - Tech Times
FDA Panel Rejects Deramiocel Evidence as Lancet Validates Same Trial Data  Tech Times
dlvr.it
July 30, 2026 at 8:52 PM
secwatch.bsky.social
🚨 JUST IN: $CAPR
FDA Advisory Committee set for July 29 to review Capricor's Deramiocel BLA; PDUFA date Aug 22

#SEC #stocks #investing #CAPR
🔗 secwatch.observer
FDA Advisory Committee set for July 29 to review Capricor's Deramiocel BLA; PDUFA date Aug 22
June 26, 2026 at 11:14 PM
stemcells.bsky.social
ICYMI: Could Capricor’s report of strong data on deramiocel for Duchenne Muscular Dystrophy spark FDA approval? I think there's a good chance ipscell.com/2025/12/coul... It reported very impressive data in a PR #stemcells #stemcell $CAPR
Could Capricor's report of strong data on deramiocel for Duchenne spark FDA approval? - The Niche
Stem cell biologist discusses the meaning of more Capricor data on cell therapy deramiocel for Duchenne Muscular Dystrophy.
ipscell.com
December 6, 2025 at 4:17 PM
thelancet.com
Bloodstream-delivered cell therapy slows muscle decline in young people with Duchenne muscular dystrophy, phase 3 trial finds.

Explore the research 👉 spkl.io/633237OMr7
Figure: Change from baseline in musculoskeletal and cardiac endpoints up to month 12. (A) PUL2.0 total score for the ITT population. (B) PUL2.0 mid-level score for the ITT population. (C) Left ventricular ejection fraction for the ITT population. (D) Left ventricular ejection fraction for the cardiomyopathy population. Each graph shows observed mean changes from baseline at baseline, month 6, and month 12 in the deramiocel (blue) and placebo (green) with accompanying standard errors (indicated by error bars). Panels (A) and (B) show the musculoskeletal measures of PUL2.0 total and mid-level scores, respectively, in the ITT population. Both panel (A) and (B) feature dual y axes, the left showing the mean observed percentage change and the right showing the observed raw mean change on the absolute scale. Panels (C) and (D) feature observed raw mean change from baseline in left ventricular ejection fraction for the ITT population and the cardiomyopathy population, respectively.
August 23, 2026 at 11:15 AM
biorxivpreprint.bsky.social
A Novel In Vitro Potency Assay Demonstrating the Anti-Fibrotic Mechanism of Action of CDCs in Deramiocel https://www.biorxiv.org/content/10.1101/2025.09.18.675440v1
September 21, 2025 at 4:30 AM
oligogirl.bsky.social
#apaperaday Again on stem cell treatment. F Duchenne only this time, WITH a scientific rationale. The pick is by Rogers et al in Stem Cell Reports on cardiosphere derived cells tested in mdx mice. This is the method of Capricor Therapeutics (deramiocel). DOI: 10.1016/j.stemcr.2025.102468
April 17, 2025 at 6:30 AM
newsen.bsky.social
Investors in Capricor Therapeutics Urged to Act Before Class Action Deadline#United_States#San_Francisco#Hagens_Berman#deramiocel#Capricor_Therapeutics
Investors in Capricor Therapeutics Urged to Act Before Class Action Deadline
Investors facing significant losses from Capricor Therapeutics are encouraged to lead a class action lawsuit by the September 28, 2026 deadline.
third-news.com
September 25, 2026 at 4:22 PM
dmdwarrior.com
Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy

👉 Read More: dmdwarrior.com

#dmd #duchenne #deramiocel #capricor
Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy Capricor Therapeutics, a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the U.S. Food and Drug Administration (“FDA”) has accepted for review its Biologics License Application (“BLA”) seeking full approval for deramiocel, an investigational cell therapy, as a treatment for patients diagnosed with Duchenne muscular dystrophy (“DMD”) cardiomyopathy.
March 4, 2025 at 1:33 PM
quantli.bsky.social
Capricor Therapeutics Receives FDA Advisory Committee Meeting Date for Deramiocel: The FDA Cellular, Tissue, and Gene Therapies Advisory Committee will convene on July 29, 2026 to review Capricor's application for Deramiocel, an investigational cell therapy for… #MarketUpdates Follow Us for more
Capricor Therapeutics Receives FDA Advisory Committee Meeting Date for Deramiocel
The FDA Cellular, Tissue, and Gene Therapies Advisory Committee will convene on July 29, 2026 to review Capricor's application for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy. The BLA is supported by positive Phase 3 HOPE-3 trial results and long-term data from the HOPE-2 extension study. The PDUFA target action date remains August 22, 2026.
quantli.com
July 27, 2026 at 10:10 PM